The Cannabulletin: Three Global Cannabis Signals From This Week

This week’s Cannabulletin is about regulatory signal, not noise.

While our longer feature pieces this week focus on specific Canada and Europe operating questions, there are three other developments worth keeping on the industry radar because they say something broader about where cannabis policy and market control are heading.

Here is the short version.

1. The US may be inching back toward a formal CBD enforcement framework

One of the more important quiet developments in the global cannabis-adjacent regulatory landscape is the US FDA’s cannabidiol policy file moving through federal review again.

The White House regulatory review system shows a notice-stage item titled Cannabidiol (CBD) Products Compliance and Enforcement Policy received on March 13, 2026. On its own, that does not tell us what the final policy will say. But it does tell us that CBD remains a live federal rulemaking and enforcement question in the world’s biggest consumer market.

Why it matters:

the CBD category still suffers from regulatory ambiguity in the US
any clearer enforcement posture could reshape risk for consumer brands, retailers, and investors
global operators should remember that “US scale” and “US clarity” are still not the same thing

This is worth watching closely because changes in the US CBD environment tend to ripple far beyond the US itself, especially in how international businesses think about wellness positioning, compliance risk, and future cannabinoid category design.

2. France still has continuity, but not final clarity, on medical cannabis

France remains one of the best examples of how politically significant cannabis reform can still move slowly in operational terms.

Official public guidance has been clear that the country’s medical cannabis experiment ended on December 31, 2024 and that the transition period for existing patients ran through March 31, 2026. In March 2025, French public-service guidance said the next step was the notification of the framework texts to the European Commission. Industry reporting in early 2026 then suggested current patients would receive a further extension beyond the March 31, 2026 deadline while the permanent framework still lagged.

Why it matters:

patient continuity is being protected, which is essential
but the delay also shows how hard it is to turn pilot logic into a durable national operating framework
for Europe, France remains a reminder that regulatory momentum and market readiness do not always move at the same speed

For companies watching Europe, France is still more of a policy-watch market than a clear commercial launch market.

3. The UK’s cannabis story is still being shaped by border and enforcement data

The UK is not generating its main cannabis headlines through access reform. It is generating them through enforcement scale.

New Home Office statistics for the year ending March 2025 show the largest quantity of herbal cannabis ever seized since the series began in 1973, with a total of 137.21 tonnes seized by police and Border Force. Border Force alone seized 126.98 tonnes of herbal cannabis, accounting for 93% of the herbal cannabis quantity seized.

Why it matters:

it reinforces how central border enforcement remains to the UK cannabis narrative
it highlights the scale of illicit supply pressure still moving through the market
it also shows how far the UK remains from the kinds of policy experiments now being tested elsewhere in Europe

For international operators, that means the UK remains a market to watch through enforcement, medicine, and institutional access, not through a near-term adult-use opening story.

Why these three signals matter together

Put side by side, these stories point to a larger pattern.

The global cannabis sector is not moving in one clean direction. Instead, major jurisdictions are still wrestling with different versions of the same core problem:

how to define a credible CBD framework
how to move from pilot access to stable medical architecture
how to respond to persistent illicit-market pressure

That is why a weekly read like this matters. Not because each item instantly changes the market, but because together they show what regulators are struggling to solve.

The short takeaway

This week’s global picture is clear enough:

the US is still trying to define CBD oversight
France is still trying to turn continuity into a permanent medical framework
the UK is still telling a cannabis story through seizure data

Different countries. Different policy stages. Same lesson.

Cannabis remains a governance problem before it becomes a stable market.

1. The US may be inching back toward a formal CBD enforcement framework

2. France still has continuity, but not final clarity, on medical cannabis

3. The UK’s cannabis story is still being shaped by border and enforcement data

Why these three signals matter together

The short takeaway

Sources